CLINICAL_TRIALS
trial_result
· 2012-06-28
Clinical Trial Update: Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML [Phase 2]
Summary
Phase 2 clinical trial evaluating the safety and anti-disease activity of oral tosedostat (CHR-2797) in elderly patients with refractory or relapsed acute myelo…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Chroma Therapeutics | Conditions: Acute Myeloid Leukemia, AML | Phase 2 | Status: COMPLETED